Mastopathy in clinical examples: so similar and so different
https://doi.org/10.33667/2078-5631-2021-26-28-32
Abstract
Aim of study. Using specific clinical examples to analyze the therapeutic and diagnostic approaches in patients with dyshormonal breast diseases (DBD).
Material and methods. Based on the data of the anamnesis, clinical and laboratory examination (ultrasound of the mammary glands and thyroid gland, the results of hormonal examination, MRI of the brain and pituitary gland with contrast enhancement), as well as data from the literature, two clinical cases of DBD were analyzed in detail.
Results. The presented clinical data indicate that hyperprolactinemia is the main marker of hormonal distress in patients with DBD, and MRI of the brain reveals structural changes that lead to an increase in prolactin levels. With moderate hyperprolactinemia, the administration of herbal dopaminomimetics leads to a decrease in the symptoms of DBD and allows to correct the concomitant hormonal pathology.
Conclusions. It is advisable to include MRI of the brain in the scope of examination of patients with DBD, as well as to apply a differentiated approach to the management of patients. One can start therapy with herbal preparations that have a complex positive effect on the female reproductive system, Mastodynon® or Cyclodynon®.
About the Author
A. B. Khuraseva
Kursk State Medical University
Russian Federation
Russian Federation
Khuraseva Anna B., DM Sci, associate professor, professor at Dept of Obstetrics and Gynecology
Kursk
SPIN: 5905–9909,
Researcher ID: ААВ‑6828–2020
References
1. Letyagin V.P., Vysotskaya I.V. Treatment of diffuse fibrocystic disease. Tumors of the female reproductive system. 2007; (1–2): 47–49.
2. Travina M. L., Golov L.B. Mammology in pediatric practice. Breast problems in children and adolescents. Diagnostic issues in pediatrics. 2009; (2): 73–78.
3. Alborova B. G. Modern approaches to the treatment of fibrocystic disease: Author’s abstract. dis. Cand. med. sciences. M., 2007. 23 p.
4. Bukharova T.N., Panina O.N. Breast cancer prevention. Tumors of the female reproductive system. 2007; (4): 11–13.
5. Andreeva E.N., Rozhkova N.I., Sokolova D.A. Benign dysplasia of the mammary glands: a pathogenetic vector of treatment. Research Review, Clinical Guidelines: Fact Sheet. E.N. Andreeva, N.I. Rozhkova, D.A. Sokolov. M.: Editorial office of the journal Status Praesens, 2016. 24 p.
6. Kataria K., Dhar A., Srivastava A. et al. A Systematic review of current understanding and management of mastalgia. Indian J Surg 2014; 76 (3): 217–22. DOI: 10.1007/s12262–013–0813–8. PMID: 25177120.
7. Serov V.N., Prilepskaya V.N., Ovsyannikova T.V. Gynecological endocrinology. M. MEDpress-inform, 2006. 520 p.
8. Binart N., Bachelot A., Bouilly J. Impact of prolactin receptor isoforms on reproduction. Trends Endocrinol Metab. 2010; 21 (6): 362–368. DOI: 10.1016/j.tem.2010.01.008. PMID: 20149678.
9. Hooper D.J. Attitudes, awareness, compliance and preferences among hormonal contraception users: a global, cross-sectional, self-administered, online survey. Clin. Drug. Invest. 2010; 30 (11): 749–763. DOI: 10.2165/11538900–000000000–00000. PMID: 20818837.
10. Kogan I. Yu. Fibrocystic changes in the mammary glands (mastopathy) and hormonal contraception. Russian Bulletin of Obstetrician-Gynecologist. 2009; 9 (3): 35–40.
11. Benign Breast Diseases: A Guide to Diagnosis and Treatment. Ed. O.S. Filippov. M.: MEDpress-inform, 2007. 112 p.
12. Lasachko S.A., Holodnyak T.I. Features of the state of the mammary glands and thyroid gland in patients of reproductive age with a history of loss of the desired pregnancy in the first trimester. Wschodnioeuropejskie Czasopismo Naukowe (East European Scientific Journal). 2016; 12 (1): 69–75.
13. A.V. Ledina, V.N. Prilepskaya The effectiveness of the treatment of mastalgia, which has arisen against the background of taking combined oral contraceptives, with the preparation of the extract of Vitex Agnus Castus. Obstetrics and gynecology. 2011; 7–1: 63–67.
14. Radzinsky V. E., Ordiyants I. M., Maslennikova M. N., Pavlova E. A., Kardanova V.V. Possibilities of therapy for a combination of uterine fibroids and benign dysplasias of the mammary glands. Obstetrics and Gynecology, 2013; 4: 44–47.
15. Clinical guidelines of the Ministry of Health of the Russian Federation No. 598 «Benign breast dysplasia» 2020. https://cr.minzdrav.gov.ru/schema/598_1. Accessed from 28.05.2021.
16. Suturina L.V., Popova L.N. The effect of bromocriptine and Cyclodinone on clinical symptoms and prolactin levels in women with reproductive age hyperprolactinemia. Questions of gynecology, obstetrics and perinatology. 2010; 9 (2): 41–43.
17. Smetnik V.P., Butareva L.B. Experience of using phytopreparation Agnucaston (Cyclodinone®) in patients with insufficiency of the corpus luteum and hyperprolactinemia. Reproduction problems. 2005; 5: 1–4.
18. I.V. Kuznetsova Uspenskaya Yu.B., Dil V.V. et al. Use of herbal dopaminomimetics in adolescents and young women with irregular menstrual cycles. Obstetrics and gynecology. 2015; 11: 70–77.
19. Podzolkova N. M., Poletova T. N. Glazkova O. L. et al. Clinical evaluation of non-hormonal monotherapy for menstrual dysfunction. Questions of gynecology, obstetrics and perinatology. 2009; 8 (3): 33–36.
20. Artymuk N.V., Kondratyeva T.A., Tachkova O.A. Principles of therapy for patients with infertility and insufficiency of the luteal phase of the menstrual cycle. Questions of gynecology, obstetrics and perinatology. 2009; 8 (4): 31–35.
Review
For citations:
Khuraseva A.B. Mastopathy in clinical examples: so similar and so different. Medical alphabet. 2021;(26):28-32. (In Russ.) https://doi.org/10.33667/2078-5631-2021-26-28-32
Views:
346
Email this article 